Blog Drug Development Drug Pricing 
STAT
JUNE 4, 2024
Our reporters Olivia Goldhill and Meghana Keshavan will be live-blogging the meeting all day — tune in here. It’s a critical meeting — MDMA could be the first Schedule I psychedelic to be deemed to have a medical use. Read the rest…
Pharma Marketing Network
MARCH 13, 2025
However, growing concerns about drug pricing, misleading claims, and overprescription have led policymakers to consider banning pharma ads from television altogether. SEO-optimized blog content helps brands rank higher in search results. Without TV ads, pharma marketers must pivot toward alternative channels.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Putting Patients First Blog
MAY 22, 2023
Driven by the work of the Food and Drug Administration on patient-focused drug development (PFDD), many companies in the biopharmaceutical community have devoted significant resources to better understand patient populations and are working to bring to market products that best suit their needs. Sincerely, Randall L.
FDA Law Blog: Biosimilars
APRIL 2, 2024
Perhaps unsurprisingly given the extraordinary focus on drug pricing in the last decade, generic competition—FDA’s only real way to have an effect on drug pricing—tops this year’s list. FDA believes this change would effectuate timelier and more cost-efficient generic drug development.”
Definitive Healthcare
FEBRUARY 23, 2024
Resource Type E-Books & How-To Guides Blog How-To Guide Healthcare Insight Medical claims 101: What you need to know How to sell effectively to healthcare facilities and executives using the right… Hospital payor mix by state Image Image Image ","nextArrow":" ","appendArrows":".coh-slider-nav-bottom","dots":false,"draggable":true,"swipe":true,"fade":false,"vertical":false,"speed":700,"cssEase":"ease","pauseOnHover":false,"pauseOnDotsHover":false,"autoplay":false,"rows":0},"sm":{"slidesToS
Express Pharma
JULY 27, 2024
It encourages pharmaceutical companies to invest heavily in discovering new drugs, developing innovative treatments, and improving healthcare outcomes. Excessive IPR protection can lead to exorbitant drug prices, making life-saving medications inaccessible to millions of people, particularly in developing countries like India.
Express Pharma
SEPTEMBER 6, 2023
Not only will this precipitate into lower treatment costs and ensure equitable biopharma access for Indian patients, but could also peg Indian pharma companies to become global market leaders in the biosimilars segment and effect a major change in drug pricing standards. appeared first on Express Pharma.
Expert insights. Personalized for you.
209 
Let's personalize your content